Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD (TAP2)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by University of California, San Francisco
United States Department of Defense
San Francisco Veterans Affairs Medical Center
Northern California Institute of Research and Education
Information provided by (Responsible Party):
University of California, San Francisco Identifier:
First received: November 9, 2012
Last updated: October 25, 2016
Last verified: October 2016
The goal of this project is to improve the treatment of veterans with co-occurring alcohol dependence and posttraumatic stress disorder (PTSD). The PI and co-investigators will conduct a controlled clinical trial of topiramate for the treatment of these co-occurring disorders.

Condition Intervention Phase
Alcohol Dependence
Posttraumatic Stress Disorder (PTSD)
Drug: Topiramate
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD

Resource links provided by NLM:

Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • Change in alcohol use as assessed by the Alcohol Timeline Followback (TLFB) [ Time Frame: Baseline to Week 12 ]
    Using a calendar, participants provide retrospective estimates of daily drinking over a specified time period.

Secondary Outcome Measures:
  • Change in PTSD symptom severity as assessed by the PTSD Checklist (PCL) [ Time Frame: Baseline to Week 12 ]
    The PCL is a 17-item self-report measure reflecting DSM-IV symptoms of PTSD. A total symptom severity score (range = 17-85) can be obtained by summing the scores from each of the 17 items that have response options ranging from 1 "Not at all" to 5 "Extremely".

  • Change in impulsivity as assessed by Delay Discounting [ Time Frame: Baseline to Week 12 ]
    The DD task provides a measure of impulsivity by evaluating discount rates for rewards delayed by 10 seconds.

  • Change in risk-taking behavior as assessed by the Balloon Analogue Risk Task (BART) [ Time Frame: Baseline to Week 12 ]
    The Balloon Analogue Risk Task (BART) is a computerized measure of risk taking behavior.

  • Change in decision-making behavior as assessed by the Iowa Gambling Task (IGT) [ Time Frame: Baseline to Week 12 ]
    The Iowa Gambling Task (IGT) is a computerized assessment that evaluates decision making mediated by the prefrontal cortex by tracking the selection of avantageous or disadvantageous electronic cards from four desks.

Estimated Enrollment: 150
Study Start Date: February 2013
Estimated Study Completion Date: October 2017
Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Topiramate
Topiramate capsules daily - up to 300 mg
Drug: Topiramate
Placebo Comparator: Placebo
Placebo capsules daily - up to 300 mg
Drug: placebo


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male and female veterans
  2. Ages18 to 69 (inclusive)
  3. Current DSM-IV diagnosis of PTSD
  4. Current (past month) DSM-IV diagnosis of an Alcohol Dependence
  5. Level of drinking must meet criteria for "at-risk " or "heavy" drinking by NIAAA threshold (NIAAA 2007): at least 15 standard drinks per week on average over the 4 weeks prior to study entry for men and at least 8 standard drinks per week on average for women.
  6. Subjects must express a desire to reduce alcohol consumption with the possible long-term goal of abstinence.
  7. Female subjects must have a negative urine pregnancy test and must be either postmenopausal for at least one year, or practicing an effective method of birth control (e.g., surgically sterile, spermicide with barrier, male partner sterilization; or abstinent and agrees to continue abstinence or to use an acceptable method of contraception, as listed above, should sexual activity commence)
  8. Subjects must have a Breath Alcohol Concentration (BAC) of < 0.02% when signing informed consent.

Exclusion Criteria:

  1. Psychotic disorders, bipolar disorder, dementia, or other psychiatric disorders judged to be unstable.
  2. Subjects known to have clinically significant unstable medical conditions, including but not limited to:

    • Clinically significant renal disease and/or impaired renal function as defined by clinically significant elevation of blood urea nitrogen (BUN) or creatinine or an estimated creatinine clearance of < 60 mL/min
    • AST and/or ALT >5 times the upper limit of the normal range and/or an increased serum bilirubin >2 times the upper limit of normal.
    • Seizure disorders
  3. History of glaucoma.
  4. History of kidney stones.
  5. Concurrent participation in another treatment study.
  6. Female patients who are pregnant or lactating.
  7. Current Topiramate use or use within the past 4 weeks.
  8. Current medications for alcohol dependence (disulfiram, naltrexone, or acamprosate) or use in the past week.
  9. Needing acute medical detoxification from alcohol based on a score of 12 or more on the Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-AD);
  10. Subjects who are legally mandated to participate in an alcohol treatment program.
  11. Subjects who have had a suicide attempt in the past 6 months or suicidal ideation in the 90 days prior to enrollment.
  12. Subjects who have previously been treated with topiramate for any reason and discontinued treatment due to an adverse event or due to a hypersensitivity reaction to topiramate,
  13. Subjects with seizure disorders that require anticonvulsant medications
  14. Subjects currently being treated with another anticonvulsant.
  15. Subjects who in the opinion of the investigator should not be enrolled in the study because of the precautions, warnings or contraindications outlined in the topiramate package insert.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01749215

Contact: Steven L. Batki, MD 415/221-4810 ext 23671
Contact: Brooke A. Lasher, BA 415/221-4810 ext 24495

United States, California
San Francisco VA Medical Center Recruiting
San Francisco, California, United States, 94121
Principal Investigator: Steven L. Batki, MD         
Sponsors and Collaborators
University of California, San Francisco
United States Department of Defense
San Francisco Veterans Affairs Medical Center
Northern California Institute of Research and Education
Principal Investigator: Steven L. Batki, MD University of California, San Francisco
  More Information

Responsible Party: University of California, San Francisco Identifier: NCT01749215     History of Changes
Other Study ID Numbers: PT110423
W81XWH-11-PHTBI-BAPHA ( Other Identifier: Department of Defense )
Study First Received: November 9, 2012
Last Updated: October 25, 2016

Keywords provided by University of California, San Francisco:
alcohol dependence

Additional relevant MeSH terms:
Stress Disorders, Post-Traumatic
Stress Disorders, Traumatic
Trauma and Stressor Related Disorders
Mental Disorders
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Neuroprotective Agents
Protective Agents
Anti-Obesity Agents processed this record on May 23, 2017